Literature DB >> 21113648

Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application.

Sabine Ott1, Andreas Wolfram Henkel, Maria Kerstin Henkel, Zoran B Redzic, Johannes Kornhuber, Jens Wiltfang.   

Abstract

Neuritic amyloid plaques and neurofibrillary tangles, consisting of hyperphosphorylated tau protein, are the hallmarks of Alzheimer disease. It is not clear so far, how both structures are functionally and physiologically connected. We have investigated the role of Aβ1-42 on hyperphosphorylation and aggregation of tau in SY5Y cells by transfection and overexpression with two tau constructs, a shortened wildtype tau (2N4R) and a point mutation tau (P301L), found in fronto-temporal dementia. It was found that the tau protein becomes hyperphosphorylated and forms large aggregates inside cells, visualized by immunofluorescence, after short incubation of 90 min with preaggregated Aβ1-42. In Addition, Aβ1-42 caused a decrease of tau solubility in both tau constructs in this relatively short time period. Taken together, these experiments suggest that pathological preaggregated Aβ1-42 in physiological concentrations quickly induces hyperphosphorylation and pathological structural changes of tau protein and thereby directly linking the 'amyloid hypothesis' to tau pathology, observed in Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21113648     DOI: 10.1007/s11010-010-0671-7

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

1.  Early phase of amyloid beta42-induced cytotoxicity in neuronal cells is associated with vacuole formation and enhancement of exocytosis.

Authors:  Meng Lu Liu; Seong Tshoo Hong
Journal:  Exp Mol Med       Date:  2005-12-31       Impact factor: 8.718

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo.

Authors:  Angela L Guillozet-Bongaarts; Michael E Cahill; Vincent L Cryns; Matthew R Reynolds; Robert W Berry; Lester I Binder
Journal:  J Neurochem       Date:  2006-04-05       Impact factor: 5.372

4.  Tau protein is hyperphosphorylated in a site-specific manner in apoptotic neuronal PC12 cells.

Authors:  J Zhang; G V Johnson
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

5.  Shift from fetal-type to Alzheimer-type phosphorylated Tau proteins in SKNSH-SY 5Y cells treated with okadaic acid.

Authors:  L Dupont-Wallois; P E Sautière; C Cocquerelle; B Bailleul; A Delacourte; M L Caillet-Boudin
Journal:  FEBS Lett       Date:  1995-01-03       Impact factor: 4.124

Review 6.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

7.  Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease.

Authors:  L M Bierer; P R Hof; D P Purohit; L Carlin; J Schmeidler; K L Davis; D P Perl
Journal:  Arch Neurol       Date:  1995-01

Review 8.  Filamentous nerve cell inclusions in neurodegenerative diseases.

Authors:  M Goedert; M G Spillantini; S W Davies
Journal:  Curr Opin Neurobiol       Date:  1998-10       Impact factor: 6.627

9.  A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads.

Authors:  E Braak; H Braak; E M Mandelkow
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

10.  Okadaic acid disrupts clusters of synaptic vesicles in frog motor nerve terminals.

Authors:  W J Betz; A W Henkel
Journal:  J Cell Biol       Date:  1994-03       Impact factor: 10.539

View more
  8 in total

1.  A partially folded structure of amyloid-beta(1-40) in an aqueous environment.

Authors:  Subramanian Vivekanandan; Jeffrey R Brender; Shirley Y Lee; Ayyalusamy Ramamoorthy
Journal:  Biochem Biophys Res Commun       Date:  2011-06-25       Impact factor: 3.575

2.  Caffeoylquinic acids in Centella asiatica protect against amyloid-β toxicity.

Authors:  Nora E Gray; Jeff Morré; Jeremiah Kelley; Claudia S Maier; Jan F Stevens; Joseph F Quinn; Amala Soumyanath
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

3.  Atorvastatin ameliorates cognitive impairment, Aβ1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.

Authors:  Dongsheng Zhou; Huaxia Liu; Chenli Li; Fangyan Wang; Yaosheng Shi; Lingjiang Liu; Xin Zhao; Aiming Liu; Junfang Zhang; Chuang Wang; Zhongming Chen
Journal:  Metab Brain Dis       Date:  2016-02-16       Impact factor: 3.584

4.  Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study.

Authors:  Fumihiko Yasuno; Hiroyuki Minami; Hideyuki Hattori
Journal:  Int J Geriatr Psychiatry       Date:  2020-11-15       Impact factor: 3.485

5.  Chaperone-dependent Neurodegeneration: A Molecular Perspective on Therapeutic Intervention.

Authors:  Aaron Carman; Sarah Kishinevsky; John Koren; Wenjie Lou; Gabriela Chiosis
Journal:  J Alzheimers Dis Parkinsonism       Date:  2013-04

Review 6.  Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?

Authors:  Joanna Kocot; Dorota Luchowska-Kocot; Małgorzata Kiełczykowska; Irena Musik; Jacek Kurzepa
Journal:  Nutrients       Date:  2017-06-27       Impact factor: 5.717

7.  Racemization in Post-Translational Modifications Relevance to Protein Aging, Aggregation and Neurodegeneration: Tip of the Iceberg.

Authors:  Victor V Dyakin; Thomas M Wisniewski; Abel Lajtha
Journal:  Symmetry (Basel)       Date:  2021-03-11       Impact factor: 2.713

8.  The Protective Effect of Vanadium on Cognitive Impairment and the Neuropathology of Alzheimer's Disease in APPSwe/PS1dE9 Mice.

Authors:  Zhijun He; Shuangxue Han; Huazhang Zhu; Xia Hu; Xiaoqian Li; Chaofan Hou; Chong Wu; Qingguo Xie; Nan Li; Xiubo Du; Jiazuan Ni; Qiong Liu
Journal:  Front Mol Neurosci       Date:  2020-03-10       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.